Literature DB >> 2304360

Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia.

V M Santana1, R K Dodge, W M Crist, G K Rivera, A T Look, F G Behm, S C Raimondi, C H Pui.   

Abstract

Adolescents had lower rates of remission induction and shorter event-free survival than younger children in this study of consecutively treated patients with acute lymphoblastic leukemia (ALL). When compared to the younger patients (ages 1-9 years; n = 995), adolescents (ages 10-21 years; n = 338) were significantly more likely to have adverse prognostic features, including T cell phenotype, L2 blast cell morphology, higher serum lactate dehydrogenase level, higher leukocyte count, leukemic cell DNA index less than 1.16, and ploidy other than hyperdiploidy greater than 50. Within the adolescent group, outcome was worse for those older than 15 years. The increased frequency of unfavorable clinical and biologic features undoubtedly accounts in part for the poorer prognosis of adolescents with ALL. However, the independent prognostic significance of age greater than or equal to 10 years suggests that as yet unknown factors contribute to treatment failure in adolescent patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2304360

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  2 in total

Review 1.  Treatment of acute lymphoblastic leukemia in adolescents and young adults.

Authors:  Joseph M Brandwein
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

2.  Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.

Authors:  James B Nachman; Mei K La; Stephen P Hunger; Nyla A Heerema; Paul S Gaynon; Caroline Hastings; Leonard A Mattano; Harland Sather; Meenakshi Devidas; David R Freyer; Peter G Steinherz; Nita L Seibel
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.